ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1562

Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

Yeliz Yagiz Ozogul1, Yesim Ozguler2, Didar Ucar3, Ugur Uygunoglu4, Zekayi Kutlubay5, Vedat Hamuryudan6 and gulen Hatemi7, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Neurology, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Dermatology, Istanbul, Turkey, 6Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Meeting: ACR Convergence 2022

Keywords: Behçet's Syndrome, Damage Index

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Damage accrual in Behçet syndrome (BS) may progress over the years and an index that can be scored using retrospective data may be useful in measuring damage accrual over a long time and comparing different treatment strategies or patient populations. We aimed to assess the construct validity, reproducibility, sensitivity to change and feasibility of Behçet’s Disease Overall Damage Index (BODI) for use in retrospective studies, and to identify items that may be missing in BODI.

Methods: BODI was translated into Turkish with the principles of scale adaptation and translated backwards by 2 people. The study included 300 patients with at least 2 visits at 1-year intervals out of 712 consecutive BS patients admitted between 2015-2017. Correlation between BODI score of the same patient that was assessed during a face-to-face visit and that was calculated retrospectively using patient charts was evaluated using intraclass correlation coefficient (ICC). Interobserver and intraobserver correlation, correlation with disease activity and feasibility were also evaluated.

Results: The mean BODI score was 1.56 ± 1.44 SD. There was good correlation between face-to-face and retrospective evaluation (ICC 0.998; [%95CI 0.997-0.999]), good interobserver agreement (ICC 0.96 [95%CI 0.94-0.98]) and intraobserver agreement (ICC 1). No correlation with disease activity was detected (r=-0.01, p=0.5). We observed an increase in BODI score in 113 (37.6%) patients during follow-up. The main reasons for increasing BODI scores were eye, vascular and neurological involvement (Table). Items not captured by BODI were hypertension, lymphedema, liver failure, glaucoma, damage due to venous interventions and lung parenchymal involvement. The mean time to complete the form was 1.5 (1-4) minutes.

Conclusion: The validated Turkish version of BODI is convenient and applicable in terms of construct validity and can be used reliably in retrospective studies. Whether modification of BODI by adding damage items identified in this study would make it an even better scale warrants further studies.

Supporting image 1

Table. Demographic features and BODI scores of BS patients


Disclosures: Y. Yagiz Ozogul, None; Y. Ozguler, UCB, Novartis, Pfizer; D. Ucar, None; U. Uygunoglu, None; Z. Kutlubay, None; V. Hamuryudan, Celgene, AbbVie/Abbott, Novartis, UCB; g. Hatemi, Celgene, UCB, Novartis, AbbVie/Abbott.

To cite this abstract in AMA style:

Yagiz Ozogul Y, Ozguler Y, Ucar D, Uygunoglu U, Kutlubay Z, Hamuryudan V, Hatemi g. Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/validation-of-behcets-disease-overall-damage-index-bodi-for-retrospective-studies-and-a-proposal-for-modification/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-behcets-disease-overall-damage-index-bodi-for-retrospective-studies-and-a-proposal-for-modification/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology